Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-DC in End-stage IPF
NCT07329959Phase 1Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Feb 2026
- Primary completion
- Aug 2028
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
Phase 1, open-label, single-arm trial of FAP-targeted immunosuppressive CAR-DC in idiopathic pulmonary fibrosis (IPF), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Safety and Efficacy of targeted FAP immunosuppressive CAR-DC at 6 months. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
FAP-targeted immunosuppressive CAR-DC
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07329959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07329959.